AbbVie (ABBV) Deferred Taxes (2019 - 2026)
AbbVie (ABBV) reported Deferred Taxes of $137.0 million for Q1 2026, up 589.29% year-over-year from $19.9 million in Q1 2025, and up 135.58% on a QoQ basis from -$385.0 million in Q4 2025.
AbbVie (ABBV) has 8 years of Deferred Taxes data on file, last reported at $137.0 million in Q1 2026.
- Quarterly Deferred Taxes rose 589.29% year-over-year to $137.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$327.0 million (up 69.94% YoY) and the FY2025 annual result came in at -$492.0 million, up 66.05% from the prior year.
- Deferred Taxes climbed to $137.0 million in Q1 2026 per ABBV's latest filing, from -$385.0 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $193.0 million in Q3 2025 and bottomed at -$1.4 billion in Q4 2023.
- The 5-year median for Deferred Taxes is -$368.0 million (2023), against an average of -$389.6 million.
- The widest annual swing landed in 2022, when Deferred Taxes plunged 1726.47%; it then jumped 589.29% in 2026.
- Tracing ABBV's Deferred Taxes over 5 years: stood at -$516.0 million in 2022, then slumped by 169.57% to -$1.4 billion in 2023, then surged by 44.86% to -$767.0 million in 2024, then jumped by 49.8% to -$385.0 million in 2025, then soared by 135.58% to $137.0 million in 2026.
- Per Business Quant, the three latest ABBV Deferred Taxes figures stand at $137.0 million (Q1 2026), -$385.0 million (Q4 2025), and $193.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 1.48 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 159.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 137.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 161.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 137.00 Mn |
| Dec 31, 2025 | -385.00 Mn |
| Sep 30, 2025 | 193.00 Mn |
| Jun 30, 2025 | -272.00 Mn |
| Mar 31, 2025 | -28.00 Mn |
| Dec 31, 2024 | -767.00 Mn |
| Sep 30, 2024 | -277.00 Mn |
| Jun 30, 2024 | -16.00 Mn |
| Mar 31, 2024 | -389.00 Mn |
| Dec 31, 2023 | -1.39 Bn |
| Sep 30, 2023 | -863.00 Mn |
| Jun 30, 2023 | -368.00 Mn |
| Mar 31, 2023 | -267.00 Mn |
| Dec 31, 2022 | -516.00 Mn |
| Sep 30, 2022 | -621.00 Mn |
| Jun 30, 2022 | -600.00 Mn |
| Mar 31, 2022 | -194.00 Mn |
| Dec 31, 2021 | -745.00 Mn |
| Sep 30, 2021 | -34.00 Mn |
| Jun 30, 2021 | -91.00 Mn |
| Mar 31, 2021 | -28.00 Mn |
| Dec 31, 2020 | -1.83 Bn |
| Sep 30, 2020 | -241.00 Mn |
| Jun 30, 2020 | -76.00 Mn |
| Mar 31, 2020 | -181.00 Mn |
| Dec 31, 2019 | 199.00 Mn |
| Sep 30, 2019 | -149.00 Mn |